IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0728072
(2003-12-04)
|
등록번호 |
US-7702399
(2010-05-20)
|
발명자
/ 주소 |
- Heil, Ron
- Haefner, Paul A.
- Cates, Adam W.
- Wagner, Darrell Orvin
- Lindstrom, Curtis Charles
|
출원인 / 주소 |
|
대리인 / 주소 |
Hollingsworth & Funk, LLC
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
110 |
초록
▼
An implantable subcutaneous device includes a lead and electrode for cardiac monitoring and intervention. The device has an implantable lead including a lead body, a subcutaneous electrode supported by the lead body and a pharmacological agent impelled from the device using phoresis. The pharmacolog
An implantable subcutaneous device includes a lead and electrode for cardiac monitoring and intervention. The device has an implantable lead including a lead body, a subcutaneous electrode supported by the lead body and a pharmacological agent impelled from the device using phoresis. The pharmacological agent provides a therapeutic treatment to subcutaneous non-intrathoracic tissue. A method of implanting subcutaneous leads involves providing a lead including a lead body, a subcutaneous electrode, and a pharmacological agent and using phoresis to impel the pharmacological agent into subcutaneous non-intrathoracic tissue surrounding the lead.
대표청구항
▼
What is claimed is: 1. An implantable cardiac system, comprising: a cardiac electrode, the electrode configured for subcutaneous placement within a patient and for one or both of cardiac monitoring and cardiac electrical stimulation; an implantable can; a pharmacological agent provided along an ext
What is claimed is: 1. An implantable cardiac system, comprising: a cardiac electrode, the electrode configured for subcutaneous placement within a patient and for one or both of cardiac monitoring and cardiac electrical stimulation; an implantable can; a pharmacological agent provided along an exterior surface of the implantable can; a power source; and a driving arrangement coupled to the can, the driving arrangement comprising a polyvinylidene fluoride layer and a conducting surface coating along the polyvinylidene fluoride layer and said driving arrangement in electrical connection with the power source, the driving arrangement configured to provide sonophoresis delivery of the pharmacological agent from the exterior surface along which the pharmacological agent is provided to subcutaneous tissue by power source electrical activation of the conducting surface coating causing movement of the polyvinylidene fluoride layer. 2. The system according to claim 1, further comprising a rigid elongated support structure coupled to the can, wherein the cardiac electrode is provided on the rigid elongated support structure. 3. The system according to claim 2, wherein the rigid elongated support structure is configured to maintain the cardiac electrode and a second electrode on the can in opposition with respect to the ventricles of the heart. 4. The system according to claim 1, further comprising an implantable pharmacological agent reservoir within the can. 5. The system according to claim 4, further comprising a micro-pump configured to facilitate transport of the pharmacological agent from the reservoir to the exterior surface along which the pharmacological agent is provided. 6. The system according to claim 1, wherein the driving arrangement is configured to generate an acoustic field that impels the pharmacological agent into subcutaneous tissue. 7. The system according to claim 1, wherein the pharmacological agent is disposed along the conducting surface coating. 8. The system according to claim 1, wherein the housing serves as an electrical ground for the driving arrangement. 9. The system according to claim 1, wherein the driving arrangement is configured to generate an ultrasonic field that drives the pharmacological agent into subcutaneous tissue. 10. The system according to claim 1, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driving arrangement facilitates phoresis delivery of the pharmacological agent after delivery of electrical cardiac stimulation therapy. 11. The system according to claim 1, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driving arrangement facilitates phoresis delivery of the pharmacological agent before delivery of electrical cardiac stimulation therapy. 12. The system according to claim 1, wherein the pharmacological agent is disposed on the polyvinylidene fluoride layer. 13. The system according to claim 1, wherein the driving arrangement is configured to deliver an AC signal alternating at an ultrasonic frequency to the conducting surface coating to provide sonophoresis delivery of the pharmacological agent. 14. The system according to claim 1, wherein the driving arrangement is configured to deliver a DC bias voltage with an AC signal alternating at an ultrasonic frequency to the conducting surface coating to provide sonophoresis delivery of the pharmacological agent. 15. An implantable system, comprising: a can; a pharmacological agent provided on a portion of an exterior surface of the can; a power source; a can electrode, the electrode configured for subcutaneous non-intrathoracic placement within a patient and for one or both of cardiac monitoring and cardiac electrical stimulation; and a driving arrangement in electrical connection with the power source and coupled to the can, the driving arrangement comprising a polyvinylidene fluoride layer and a conducting surface coating along the polyvinylidene fluoride layer, the driving arrangement configured to provide sonophoresis delivery of the pharmacological agent from at least the portion of the exterior surface of the can to subcutaneous tissue by power source electrical activation of the conducting surface coating and movement of the polyvinylidene fluoride layer. 16. The system according to claim 15, wherein the driving arrangement is configured to generate an acoustic field that impels the pharmacological agent into subcutaneous, non-intrathoracic tissue. 17. The system according to claim 15, wherein the driving arrangement is configured to generate an ultrasonic field that drives the pharmacological agent into subcutaneous, non-intrathoracic tissue. 18. The system according to claim 15, further comprising an implantable pharmacological agent reservoir and a micro-pump configured to facilitate transport of pharmacological agent from the reservoir to the exterior surface of the can. 19. The system according to claim 15, wherein the pharmacological agent is disposed along the conducting surface coating. 20. The system according to claim 15, wherein the at least part of the driving arrangement comprises an external driver detachably coupled to the can, the external driver configured to provide power and control for phoresis delivery of the pharmacological agent during surgical implantation of the can. 21. The system according to claim 15, wherein the can comprises a porous region on the portion of the exterior surface, the pharmacological agent at least partially filling pores of the porous region. 22. The system according to claim 21, wherein the porous region comprises a doped polymer matrix. 23. The system according to claim 15, further comprising a lead body coupled to the can, wherein the lead body and the can form a rigid unitary structure having an arcuate shape. 24. The system according to claim 23, wherein the coating covers at least 25% of a surface area of the can. 25. The system according to claim 15, further comprising a lead coupled to the can, the lead comprising an electrode and a rigid elongated support structure configured to stabilize and maintain a spacing between the electrode and the implantable can in subcutaneous, non-intrathoracic tissue within the patient. 26. The system according to claim 15, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driving arrangement facilitates phoresis delivery of the pharmacological agent after delivery of electrical cardiac stimulation therapy. 27. The system according to claim 15, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driving arrangement facilitates phoresis delivery of the pharmacological agent before delivery of electrical cardiac stimulation therapy. 28. An implantable cardiac lead system, comprising: a lead body having a ground layer; a cardiac electrode coupled to the lead body, the electrode configured for subcutaneous placement in a patient and for one or both of cardiac monitoring and cardiac electrical stimulation; an implantable can coupled to the lead body; one or more conductors coupled to the electrode and disposed within the lead body; a pharmacological agent provided along one or both of the can and a longitudinal portion of an exterior surface of the lead body over the ground layer; a power source; and means, in electrical connection with the power source, for impelling the pharmacological agent into subcutaneous tissue using sonophoresis, wherein the impelling means comprises a polyvinylidene fluoride layer and a conducting surface coating along the polyvinylidene fluoride layer, and the polyvinylidene fluoride layer and the conducting surface coating are provided along one or both of the can and the longitudinal portion of the lead body along which the pharmacological agent is provided. 29. The lead system according to claim 28, wherein the impelling means comprises means for impelling the pharmacological agent using sonophoresis by electrical activation of the conducting surface coating causing movement of the polyvinylidene fluoride layer. 30. The lead system according to claim 28, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driving arrangement facilitates sonophoresis delivery of the pharmacological agent after delivery of electrical cardiac stimulation therapy. 31. The lead system according to claim 28, wherein the lead body comprises a rigid elongated support structure configured to stabilize and maintain a spacing between the cardiac electrode and the implantable can in subcutaneous, non-intrathoracic tissue within the patient. 32. A system, comprising: an implantable medical device, comprising: a can that houses circuitry configured to provide one or both of cardiac monitoring and cardiac stimulation; a lead coupled to the can, the lead comprising a lead body, a cardiac electrode coupled to the lead body, a ground layer, and one or more conductors coupled to the cardiac electrode and disposed within the lead body, the electrode configured for subcutaneous placement within a patient and for one or both of cardiac monitoring and cardiac electrical stimulation; a first pharmacological agent provided along at least a longitudinal portion of an exterior surface of the lead body; and a second pharmacological agent provided on a portion of an exterior surface of the can; and a driver apparatus detachably coupled to the implantable medical device, the driver apparatus comprising a power source and a plurality of polyvinylidene fluoride layers and a plurality of conducting surface coatings each disposed along respective polyvinylidene fluoride layers of the plurality of polyvinylidene fluoride layers, the driver apparatus configured to facilitate sonophoresis delivery of at least one of the first pharmacological agent from the longitudinal portion of the exterior surface of the lead body over the ground layer and the second pharmacological agent from the portion of the exterior surface of the can by power source electrical activation of the conducting surface coatings and movement of the polyvinylidene fluoride layers. 33. The system according to claim 32, wherein the lead comprises an rigid elongated support structure configured to stabilize and maintain a spacing between the cardiac electrode and the can in subcutaneous, non-intrathoracic tissue within the patient. 34. The system according to claim 33, wherein the lead and the can form a unitary structure having an arcuate shape. 35. The system according to claim 33, wherein the rigid elongated support structure is configured to maintain the cardiac electrode and a second electrode disposed on the can in opposition with respect to the ventricles of the heart. 36. The system according to claim 32, wherein the polyvinylidene fluoride layers and the conducting surface coatings are provided at least along the longitudinal portion of the exterior surface of the lead body. 37. The system according to claim 32, wherein the driver apparatus is configured to deliver an AC signal alternating at an ultrasonic frequency to the conducting surface coatings to provide sonophoresis delivery. 38. The system according to claim 32, wherein the driver apparatus is configured to deliver a DC bias voltage with an AC signal alternating at an ultrasonic frequency to the conducting surface coatings to provide sonophoresis delivery. 39. The system according to claim 32, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driver apparatus facilitates phoresis delivery of the pharmacological agent after delivery of electrical cardiac stimulation therapy. 40. The system according to claim 32, further comprising a controller configured to coordinate phoresis delivery of the pharmacological agent relative to electrical cardiac stimulation therapy such that the driver apparatus facilitates phoresis delivery of the pharmacological agent before delivery of electrical cardiac stimulation therapy. 41. The system according to claim 32, further comprising an implantable pharmacological agent reservoir within the can. 42. The system according to claim 41, further comprising a micro-pump configured to facilitate transport of pharmacological agent from the reservoir to the exterior surface of the lead body and the exterior surface of the can.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.